Skip to content

Calcium Autonomic Denervation Therapy for Postoperative Atrial Fibrillation in Valve Surgery with Great Left Atrium

Calcium Autonomic Denervation Therapy for Postoperative Atrial Fibrillation in Valve Surgery with Great Left Atrium

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029311
Enrollment
Unknown
Registered
2020-01-24
Start date
2020-02-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Interventions

Sponsors

Department of Cardiovascular Surgery, General Hospital of Northern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18 to 80 years; 2. Patients with prior history of AF; 3. Non-urgent or non-emergent valve surgery; 4. With MI or AS, AI disease; 5. EF > 40%; 6. LAA > 50 mm; 7. Patients undergoing heart surgery for the first time; 8. Willing to paticipant in this trial and sign the informed consent, good compliance and ability to complete follow-up.

Exclusion criteria

Exclusion criteria: 1. With a history of adult congenital heart disease or valvular disease; 2. Have taken class I or III anti-arrhythmic drugs for any arrhythmia; 3. Valve surgery is accompanied by surgery of other heart surgery; 4. Heart surgery is accompanied by surgery of other organ system; 5. Liver and kidney function abnormality (results exceed the upper limit of normal value by 3 times); 6. With valve surgery contraindications; 7. Patients suffer from other diseases who require radiotherapy, chemotherapy, and long-term hormone treatment; 8. Participated in other clinical trials; 9. Patients decline to consent.

Design outcomes

Primary

MeasureTime frame
Incidence of POAF (lasting more than 30 seconds) in both groups;

Secondary

MeasureTime frame
Days of hospital stay following surgery;Ventricular rate during AF;Inflammatory makers;Actionable AF: antiarrhythmic use (including rate-control meds), CDV, anticoagulation, use of inotropes for BP support during AF;Atrial fibrillation burden during the first week of operation;Duration of Blocking time and extracorporeal circulation;The incidence of Premature Atrial Contraction (PAC), Couplets and Nonsustained Atrial Tachyarrhythmia;2D STI;

Countries

China

Contacts

Public ContactHui-Shan Wang

Department of Cardiovascular Surgery, General Hospital of Northern Theater Command

huishanwang@hotmail.com+86 13309885095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026